Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the inclusion of Chinese and Japanese participants in future global studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-13.
Status change: Not Yet Recruiting → Completed 2026-06-09
Trial Details
NCT Number NCT06979518
Lead Sponsor GlaxoSmithKline
Conditions Pulmonary Disease, Chronic Obstructive
Enrollment 30 participants
Start Date 2025-05-20
Primary Completion 2026-04-22 (estimated)
Study Completion 2026-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-11